CellMax Life

CellMax Life is a private diagnostics company founded in 2014, headquartered in Sunnyvale, California. It has developed a proprietary circulating epithelial cell capture platform, the CMx Bio-Mimetic platform, to detect precancerous and cancerous cells from a single blood draw. The company's lead product is FirstSight, a blood test for colorectal cancer screening aimed at detecting adenomas to enable prevention. It is positioned to address a significant gap in current non-invasive screening methods, which largely miss precancerous lesions.

Proprietary Circulating Epithelial Cell (CEC) Bio-Mimetic (CMx) platform for capturing and analyzing precancerous and cancerous cells from blood, integrated with imaging, algorithm development, NGS, methylation, and protein analysis.

Competes directly with other liquid biopsy companies developing blood-based CRC screening tests, such as Guardant Health (Guardant Shield), Exact Sciences (next-gen Cologuard), and Freenome. Also competes with established stool-based tests (FIT, Cologuard) and the gold standard, colonoscopy. Differentiation hinges on claimed high sensitivity for precancerous adenomas.